Key result
Pulsed levosimendan improves symptoms, increases walk distance, and markedly cuts heart failure hospitalizations.
Why the study?
While repetitive levosimendan infusions show benefit in advanced heart failure, its use in heart failure resulting from congenital heart disease is not yet commonplace.
Does pulsed levosimendan improve symptoms and biomarkers in patients with advanced heart failure due to congenital heart disease?
Case Report (n=3)
No
Does pulsed levosimendan improve symptoms and biomarkers in patients with advanced heart failure due to congenital heart disease?
Pulsed levosimendan may be a valuable therapy to improve symptoms and reduce hospitalization in adults with advanced heart failure due to congenital heart disease.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in advanced congenital heart disease-related heart failure; leaves open efficacy in prospective trials.
BACKGROUND: Levosimendan is a non-adrenergic calcium-sensitizing agent with positive inotropic and vasodilatory effects. Its use in acute decompensation of heart failure is established. Good evidence now exists for repetitive infusions of Levosimendan to improve symptoms and reduce hospitalization in advanced heart failure (AdHF) populations. Its use in heart failure resulting from congenital heart disease is not yet commonplace. CASE SUMMARY: We present three cases in which pulsed Levosimendan was used in the management of AdHF secondary to underlying congenital heart disease. There was symptomatic and biomarker evidence of improvement. DISCUSSION: Intermittent Levosimendan may represent a valuable therapy to reduce hospitalization and improve quality of life in adults with congenital heart conditions.
No takes yet. Share an insight, caveat, or question.
Cranley et al. (2020) conducted a case report in Advanced heart failure secondary to adult congenital heart disease (n=3). Pulsed Levosimendan was evaluated on Symptomatic improvement and reduction in hospital admissions. Pulsed levosimendan administration resulted in symptomatic improvement, increased walking distance test distance, and a marked reduction in hospitalizations for acute decompensated heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: